Celebrity promotion, social media trends and direct-to-consumer advertising have created massive demand for high-cost GLP-1 drugs. With an estimated 100 million adult Americans (nearly 42%) living with obesity and manufacturers seeking expanded uses for GLP-1s, this trend shows no sign of slowing.
While effective in treating the conditions they were initially approved for – first diabetes and then weight loss related to obesity – GLP-1s are increasingly replacing lower-cost options. Doctors wrote nearly 700,000 new GLP-1 prescriptions for diabetes and obesity in February 2024 alone – up 181% from two years prior. The market is expected to grow from $46.7 billion in 2024 at a notable compounded annual growth rate of 33.2%, reaching $471.1 billion by 2032.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
